Hastings Cent Rep. 2017 Sep;47(5):5-6. doi: 10.1002/hast.762.
In this pivotal year for gene editing, the breakthrough molecular system CRISPR-Cas9 has advanced on three fronts. In under seven months, an influential scientific body-the National Academies of Sciences, Engineering, and Medicine the National Academies of Sciences, Engineering, and Medicine-cracked open the door to human germline gene editing, ownership of patents covering CRISPR-Cas9 came into much sharper focus as a result of a dispute between two parties, and experiments showing proof of concept of the most controversial of uses-altering germlines of humans-were revealed as having been successfully performed by a mainstream laboratory. Given the vast spoils that await the patent owners, final results of all patent disputes over CRISPR-Cas9 patents may stretch on for years. Meanwhile, bioethical considerations of CRISPR-Cas9 have also been contentious as the United States and other countries grapple with how best to regulate gene editing.
在这个基因编辑的关键年份，突破性的分子系统 CRISPR-Cas9 在三个方面取得了进展。在不到七个月的时间里，一个有影响力的科学机构——美国国家科学院、工程院和医学院——为人类生殖系基因编辑打开了大门，由于两党之间的争端，CRISPR-Cas9 专利的所有权变得更加引人注目，同时，证明最具争议性用途之一的概念验证实验——改变人类的生殖系——被揭示为由一个主流实验室成功进行。鉴于专利所有者将获得巨大的收益，所有关于 CRISPR-Cas9 专利的专利纠纷的最终结果可能会持续数年。与此同时，由于美国和其他国家正在努力寻找最佳的基因编辑监管方式，CRISPR-Cas9 的生物伦理考虑也颇具争议性。
